Polaris Group appointed Chien-Hsing Chang, Vice President of R&D, IMMUNOMEDICS Inc. as Chief Strategy Officer effective June 20, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
68.8 TWD | +0.29% | -2.27% | -8.99% |
05-14 | Polaris Group Announces Change of the Member of Compensation Committee | CI |
2023 | Polaris Group Announces the Appointment of K Evin Wu | CI |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-8.99% | 1.59B | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+36.50% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- 6550 Stock
- News Polaris Group
- Polaris Group Appoints Chien-Hsing Chang as Chief Strategy Officer Effective June 20, 2023